Asymchem Laboratories Tian Jin Co Ltd (SHE:002821) — Market Cap & Net Worth

$8.63 Billion USD  · CN¥59.00 Billion CNY  · Rank #2500

Market Cap & Net Worth: Asymchem Laboratories Tian Jin Co Ltd (002821)

Asymchem Laboratories Tian Jin Co Ltd (SHE:002821) has a market capitalization of $8.63 Billion (CN¥59.00 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #2500 globally and #281 in its home market, demonstrating a 6.36% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Asymchem Laboratories Tian Jin Co Ltd's stock price CN¥177.20 by its total outstanding shares 332946460 (332.95 Million). Also see Asymchem Laboratories Tian Jin Co Ltd asset portfolio for a full breakdown of the balance sheet.

Asymchem Laboratories Tian Jin Co Ltd Market Cap History: 2016 to 2026

Asymchem Laboratories Tian Jin Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $2.35 Billion to $8.63 Billion (28.77% CAGR). Also see 002821 cash flow conversion for how efficiently the company converts equity into cash flow.

Asymchem Laboratories Tian Jin Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Asymchem Laboratories Tian Jin Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Asymchem Laboratories Tian Jin Co Ltd for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

0.68x

Asymchem Laboratories Tian Jin Co Ltd's market cap is 0.68 times its annual revenue

Industry average: 3887.03x Lower than industry average

Latest Price to Earnings (P/E) Ratio

4.00x

Asymchem Laboratories Tian Jin Co Ltd's market cap is 4.00 times its annual earnings

Industry average: 1.67x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $2.35 Billion $1.10 Billion $252.74 Million 2.13x 9.29x
2017 $1.96 Billion $1.42 Billion $341.29 Million 1.38x 5.76x
2018 $2.24 Billion $1.83 Billion $428.30 Million 1.22x 5.22x
2019 $4.29 Billion $2.46 Billion $553.86 Million 1.74x 7.74x
2020 $9.93 Billion $3.14 Billion $719.74 Million 3.17x 13.80x
2021 $14.46 Billion $4.63 Billion $1.07 Billion 3.12x 13.53x
2022 $6.92 Billion $10.23 Billion $3.30 Billion 0.68x 2.10x
2023 $5.51 Billion $7.83 Billion $2.27 Billion 0.70x 2.43x
2024 $3.71 Billion $5.80 Billion $948.95 Million 0.64x 3.91x
2025 $4.53 Billion $6.67 Billion $1.13 Billion 0.68x 4.00x

Competitor Companies of 002821 by Market Capitalization

Companies near Asymchem Laboratories Tian Jin Co Ltd in the global market cap rankings as of September 16, 2026. Review Asymchem Laboratories Tian Jin Co Ltd tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Asymchem Laboratories Tian Jin Co Ltd by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
  • CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
  • Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#186 Vertex Pharmaceuticals Inc NASDAQ:VRTX $130.44 Billion $514.63
#353 Regeneron Pharmaceuticals Inc NASDAQ:REGN $78.29 Billion $774.11
#457 CSL Ltd AU:CSL $59.82 Billion AU$174.26
#506 Moderna Inc NASDAQ:MRNA $54.14 Billion $143.77

Asymchem Laboratories Tian Jin Co Ltd Historical Marketcap From 2016 to 2026

Between 2016 and today, Asymchem Laboratories Tian Jin Co Ltd's market cap moved from $2.35 Billion to $ 8.63 Billion, with a yearly change of 28.77%.

Year Market Cap Change (%)
2026 CN¥8.63 Billion +90.68%
2025 CN¥4.53 Billion +22.13%
2024 CN¥3.71 Billion -32.67%
2023 CN¥5.51 Billion -20.41%
2022 CN¥6.92 Billion -52.17%
2021 CN¥14.46 Billion +45.65%
2020 CN¥9.93 Billion +131.49%
2019 CN¥4.29 Billion +91.75%
2018 CN¥2.24 Billion +13.86%
2017 CN¥1.96 Billion -16.30%
2016 CN¥2.35 Billion --

End of Day Market Cap According to Different Sources

On Sep 16th, 2026 the market cap of Asymchem Laboratories Tian Jin Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $8.63 Billion USD
MoneyControl $8.63 Billion USD
MarketWatch $8.63 Billion USD
marketcap.company $8.63 Billion USD
Reuters $8.63 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Asymchem Laboratories Tian Jin Co Ltd

SHE:002821 China Biotechnology
Market Cap
$8.63 Billion
CN¥59.00 Billion CNY
Market Cap Rank
#2500 Global
#281 in China
Share Price
CN¥177.20
Change (1 day)
-0.23%
52-Week Range
CN¥89.50 - CN¥195.75
All Time High
CN¥358.21
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more